Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 979648, 7 pages
http://dx.doi.org/10.1155/2014/979648
Research Article

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii

Clinical Microbiology Laboratory, Faculty of Medicine & Medical Science, University of Balamand, P.O. Box 100, Tripoli, Lebanon

Received 17 July 2014; Revised 25 September 2014; Accepted 22 October 2014; Published 30 December 2014

Academic Editor: Shira Doron

Copyright © 2014 E. Dahdouh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. F. Keen III, B. J. Robinson, D. R. Hospenthal et al., “Incidence and bacteriology of burn infections at a military burn center,” Burns, vol. 36, no. 4, pp. 461–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Nowak, P. Paluchowska, and A. Budak, “Distribution of blaOXA genes among carbapenem-resistant Acinetobacter baumannii nosocomial strains in Poland,” New Microbiologica, vol. 35, no. 3, pp. 317–325, 2012. View at Google Scholar · View at Scopus
  3. R. P. Baughman, “The use of carbapenems in the treatment of serious infections,” Journal of Intensive Care Medicine, vol. 24, no. 4, pp. 230–241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. W. Nor Amilah, N. J. Noor Izani, W. K. Ng, and J. A. Haq, “A simple screening test for the detection of metallo-β-lactamase-producing Pseudomonas aeruginosa and Acinetobacter in a tertiary care hospital,” Tropical Biomedicine, vol. 29, no. 4, pp. 588–597, 2012. View at Google Scholar · View at Scopus
  5. J. M. Casellas, “Antibacterial drug resistance in Latin America: consequences for infectious disease control,” Revista Panamericana de Salud Publica, vol. 30, no. 6, pp. 519–528, 2011. View at Google Scholar · View at Scopus
  6. T. R. Walsh, “Clinically significant carbapenemases: an update,” Current Opinion in Infectious Diseases, vol. 21, no. 4, pp. 367–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Zhao and K. Drlica, “Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window,” The Journal of Infectious Diseases, vol. 185, no. 4, pp. 561–565, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Pea, “Mutant prevention concentration: is it significant in the clinical practice?” Le Infezioni in Medicina, vol. 16, no. 2, pp. 12–21, 2008. View at Google Scholar · View at Scopus
  9. J. W. Mouton, M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano, “Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 4, pp. 601–607, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. H. J. Smith, K. A. Nichol, D. J. Hoban, and G. G. Zhanel, “Stretching the mutant prevention concentration (MPC) beyond its limits,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 6, pp. 1323–1325, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Credito, K. Kosowska-Shick, and P. C. Appelbaum, “Mutant prevention concentrations of four carbapenems against Gram-negative rods,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 6, pp. 2692–2695, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. Clinical and Laboratory Standards Institute, “Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. (No. M100-S21),” Clinical and Laboratory Standards Institute, vol. 31, no. 1, 2011. View at Google Scholar
  13. F. Pasquali and G. Manfreda, “Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa,” Veterinary Microbiology, vol. 119, no. 2–4, pp. 304–310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Zarakolu, G. Metan, G. Hasçelik, and M. Akova, “Comparison of different phenotypic methods detecting extended spectrum beta-lactamases in Pseudomonas aeruginosa and Acinetobacter baumannii strains,” Mikrobiyoloji Bulteni, vol. 39, no. 3, pp. 265–272, 2005. View at Google Scholar · View at Scopus
  15. A. Bhattacharjee, S. Anupurba, A. Gaur, and M. R. Sen, “Prevalence of inducible AmpC β-lactamase-producing 32 in a tertiary care hospital in northern India,” Indian Journal of Medical Microbiology, vol. 26, no. 1, pp. 89–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. J. D. D. Pitout, P. G. Le, K. L. Moore, D. L. Church, and D. B. Gregson, “Detection of AmpC β-lactamases in Escherichia coli, Klebsiella spp., Salmonella spp. and Proteus mirabilis in a regional clinical microbiology laboratory,” Clinical Microbiology and Infection, vol. 16, no. 2, pp. 165–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Tsakris, A. Poulou, S. Pournaras et al., “A simple phenotypic method for the differentiation of metallo-β-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 8, Article ID dkq210, pp. 1664–1671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Pournaras, A. Markogiannakis, A. Ikonomidis et al., “Outbreak of multiple clones of imipenem-resistant acinetobacter baumannii isolates expressing OXA-58 carbapenemase in an intensive care unit,” Journal of Antimicrobial Chemotherapy, vol. 57, no. 3, pp. 557–561, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. P. D. Nallathamby, K. J. Lee, T. Desai, and X.-H. N. Xu, “Study of the multidrug membrane transporter of single living Pseudomonas aeruginosa cells using size-dependent plasmonic nanoparticle optical probes,” Biochemistry, vol. 49, no. 28, pp. 5942–5953, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Bereket, K. Hemalatha, B. Getenet et al., “Update on bacterial nosocomial infections,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 8, pp. 1039–1044, 2012. View at Google Scholar · View at Scopus
  21. J. Gonçalves-Pereira and P. Póvoa, “Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams,” Critical Care, vol. 15, no. 5, article R206, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. P. G. Higgins, C. Dammhayn, M. Hackel, and H. Seifert, “Global spread of carbapenem-resistant acinetobacter baumannii,” The Journal of antimicrobial chemotherapy, vol. 65, no. 2, pp. 233–238, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. S. Lestari, J. A. Severin, and H. A. Verbrugh, “Antimicrobial resistance among pathogenic bacteria in Southeast Asia,” Southeast Asian Journal of Tropical Medicine and Public Health, vol. 43, no. 2, pp. 385–422, 2012. View at Google Scholar · View at Scopus
  24. F. Scaglione, “Can PK/PD be used in everyday clinical practice,” International Journal of Antimicrobial Agents, vol. 19, no. 4, pp. 349–353, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Rybak, “Pharmacodynamics: relation to antimicrobial resistance,” The American Journal of Medicine, vol. 119, no. 6, pp. S37–S44, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Drlica and X. Zhao, “Mutant selection window hypothesis updated,” Clinical Infectious Diseases, vol. 44, no. 5, pp. 681–688, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Poirel and P. Nordmann, “Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology,” Clinical Microbiology and Infection, vol. 12, no. 9, pp. 826–836, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Ge, Z. Wei, Y. Jiang, P. Shen, Y. Yu, and L. Li, “Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China,” The Journal of Antimicrobial Chemotherapy, vol. 66, no. 5, pp. 1184–1186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. I. E. Robledo, E. E. Aquino, M. I. Santé et al., “Detection of KPC in Acinetobacter spp. in Puerto Rico,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1354–1357, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Opazo, M. Domínguez, H. Bello, S. G. B. Amyes, and G. González-Rocha, “OXA-type carbapenemases in acinetobacter baumannii in South America,” Journal of Infection in Developing Countries, vol. 6, no. 4, pp. 311–316, 2012. View at Google Scholar · View at Scopus
  31. A. Y. Peleg, H. Seifert, and D. L. Paterson, “Acinetobacter baumannii: emergence of a successful pathogen,” Clinical Microbiology Reviews, vol. 21, no. 3, pp. 538–582, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Christenson, E. K. Korgenski, and J. A. Daly, “In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 6, pp. 899–901, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Riera, G. Cabot, X. Mulet et al., “Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 9, Article ID dkr232, pp. 2022–2027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Oliver, B. R. Levin, C. Juan, F. Baquero, and J. Blázquez, “Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 11, pp. 4226–4233, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. R. White, L. Friedrich, D. Burgess, D. Warkentin, and J. Bosso, “Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa,” Antimicrobial Agents and Chemotherapy, vol. 40, no. 4, pp. 904–908, 1996. View at Google Scholar · View at Scopus
  36. T. R. Walsh, M. A. Toleman, L. Poirel, and P. Nordmann, “Metallo-β-lactamases: the quiet before the storm?” Clinical Microbiology Reviews, vol. 18, no. 2, pp. 306–325, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Gu, M. Tong, W. Zhao et al., “Prevalence and characterization of class I integrons among Pseudomonas aeruginosa and Acinetobacter baumannii isolates from patients in Nanjing, China,” Journal of Clinical Microbiology, vol. 45, no. 1, pp. 241–243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Balfour, H. M. Bryson, and R. N. Brogden, “Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections,” Drugs, vol. 51, no. 1, pp. 99–136, 1996. View at Publisher · View at Google Scholar · View at Scopus
  39. S. R. Norrby, K. L. Faulkner, and P. A. Newell, “Differentiating meropenem and imipenem/cilastatin,” Infectious Diseases in Clinical Practice, vol. 6, no. 5, pp. 291–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. P. J. Bergen, A. Forrest, J. B. Bulitta et al., “Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 11, pp. 5134–5142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. V. H. Tam, P. S. McKinnon, R. L. Akins, M. J. Rybak, and G. L. Drusano, “Pharmacodynamics of cefepime in patients with Gram-negative infections,” Journal of Antimicrobial Chemotherapy, vol. 50, no. 3, pp. 425–428, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Jaruratanasirikul and T. Sudsai, “Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 3, pp. 560–563, 2009. View at Publisher · View at Google Scholar · View at Scopus